Cellosaurus logo
expasy logo

Cellosaurus 10C5.6 (CVCL_C9FP)

[Text version]
Cell line name 10C5.6
Accession CVCL_C9FP
Resource Identification Initiative To cite this cell line use: 10C5.6 (RRID:CVCL_C9FP)
Comments Biotechnology: The monoclonal antibody produced by this hybridoma was developed into a therapeutic mAB known as Zanolimumab to be used in the treatment of rheumatoid arthritis, psoriasis, melanoma and cutaneous and peripheral T-cell lymphoma.
Doubling time: 19 hours (PubMed=9631008).
Monoclonal antibody isotype: IgG1, kappa.
Monoclonal antibody target: UniProtKB; P01730; Human CD4.
Miscellaneous: As the immunized splenic B-cells are from humanized transgenic HC2/KCo5/JHD/JCkappaD mice the produced mAB is of human origin.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_4032 (P3X63Ag8.653)
Category Hybridoma
Publications

PubMed=9631008; DOI=10.1038/nbt0796-845
Fishwild D.M., O'Donnell S.L., Bengoechea T., Hudson D.V., Harding F., Bernhard S.L., Jones D., Kay R.M., Higgins K.M., Schramm S.R., Lonberg N.
High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.
Nat. Biotechnol. 14:845-851(1996)

Patent=US8231877
Lonberg N., Kay R.M., Fishwild D.M.
Heterologous antibodies which bind human CD4.
Patent number US8231877, 31-Jul-2012

Cross-references
Biological sample resources ABCD; ABCD_AK558
Encyclopedic resources Wikidata; Q123030202
Entry history
Entry creation05-Oct-2023
Last entry update30-Jan-2024
Version number2